Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 23;15(10):19226-38.
doi: 10.3390/ijms151019226.

Stem cell treatment for Alzheimer's disease

Ming Li  1 , Kequan Guo  2 , Susumu Ikehara  3
Affiliations
Review

Stem cell treatment for Alzheimer's disease

Ming Li et al. Int J Mol Sci. .

Abstract

Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that induces dementia in older people. It was first reported in 1907 by Alois Alzheimer, who characterized the disease as causing memory loss and cognitive impairment. Pathologic characteristics of AD are β-amyloid plaques, neurofibrillary tangles and neurodegeneration. Current therapies only target the relief of symptoms using various drugs, and do not cure the disease. Recently, stem cell therapy has been shown to be a potential approach to various diseases, including neurodegenerative disorders, and in this review, we focus on stem cell therapies for AD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Escape latency of Senescence-Accelerated Mouse Prone 8 (SAMP8). (a) Untreated SAMP8; (b) SAMP8 treated with intra-bone marrow-bone marrow transplantation (IBM-BMT); and (c) SAM-resistant strains 1 (SAMR1).
Figure 2
Figure 2
Summary of Stem Cell Therapy for AD.
See this image and copyright information in PMC

References

    1. Selkoe D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2001;81:741–766. - PubMed
    1. Persson T., Popescu B.O., Cedazo-Minguez A. Oxidative stress in Alzheimer’s disease: Why did antioxidant therapy fail? Oxid. Med. Cell Longev. 2014;2014:427318. - PMC - PubMed
    1. Demuro A., Smith M., Parker I. Single-channel Ca2+ imaging implicates Aβ 1–42 amyloid pores in Alzheimer’s disease pathology. J. Cell Biol. 2011;195:515–524. - PMC - PubMed
    1. Kuhla B., Haase C., Flach K., Luth H.J., Arendt T., Munch G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J. Biol. Chem. 2007;282:6984–6991. doi: 10.1074/jbc.M609521200. - DOI - PubMed
    1. Eikelenboom P., Bate C., van Gool W.A., Hoozemans J.J., Rozemuller J.M., Veerhuis R., Williams A. Neuroinflammation in Alzheimer’s disease and prion disease. Glia. 2002;40:232–239. - PubMed

MeSH terms